Leap Therapeutics: 2 Cancer Trials Disappoint, But There Is A Silver Lining
Leap Therapeutics, Inc.'s DKN-01 trial results show mixed outcomes in cancer treatment, prompting potential future funding ...
Analysts Have Conflicting Sentiments on These Healthcare Companies: Leap Therapeutics (LPTX) and Immunovant (IMVT)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Leap Therapeutics (LPTX – Research Report) ...
Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data from Part B of the DeFianCe study ...
Leap scraps late-stage plans for gastric cancer therapy after mid-stage setback
Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric ...
The Pharma Letter1d
Leap halts gastric cancer program, changes course
Leap Therapeutics is discontinuing the development of its anti-DKK1 antibody sirexatamab in gastric cancer after the drug ...
Morningstar25d
Leap Therapeutics Inc LPTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
BioWorld3d
CRC yes, gastric no in Leap’s sirexatamab phase IIs
Some favorable and some not-so-great results from separate midstage trials testing the anti-dickkopf homolog 1 antibody sirexatamab in combo regimens for two types of gastrointestinal tumors vexed ...
Leap reports positive colorectal cancer study results
CAMBRIDGE, Mass. - Leap Therapeutics, Inc. (NASDAQ:LPTX), a clinical-stage biotech company with a market capitalization of $86 million and an overall "Fair" financial health rating according to ...